Arrhythmias & electrophysiology
The Clinical Significance of Atrial Fibrillation in Non–High-Risk Brugada Syndrome: The BruFib Study
Main finding · VAsResult — go to the resultHazard ratio 0.67Authors' conclusion
The presence of AF in non-high-risk BrS does not identify patients with higher risk of VAs. However, early-onset AF (<20 years) defines a distinct subgroup with elevated risk. Patients with AF and BrS have a significantly higher risk of SSS and stroke.
Study context
- Population
- Patients with non-high-risk Brugada syndrome
- Participants
- 686 patients
- Exposure
- Atrial fibrillation (AF) vs no AF
- AFn = 280
- Outcome
- VAs (sustained VT, VF or arrhythmic SCD)
- Follow-up
- Median 48.8 months
Methodological detailsmulticentre, 20 international centres
- Multicentre
- 20 international centres
Main finding
VAs
Hazard ratio
0.67
P = 0.58
As reported in the abstract
- Incidence of ventricular arrhythmias (VAs) (overall)
- 0.26% per year
Observational data: associations, not effects.
Further findings
Sick sinus syndrome
P = 0.047
| Outcome | AF | No AF |
|---|---|---|
| StrokeStroke occurred exclusively in the AF group | 2.5% | 0 events |
- Stroke: CHA2DS2-VA mean 0.5
VAs with early-onset AF (<20 years) (subgroup)
- Significantly higher risk of VAs with early-onset AF
- P < 0.001
Risk factors for AF
- Proband status and older age associated with AF (Cox regression)
Original publication
The Clinical Significance of Atrial Fibrillation in Non–High-Risk Brugada Syndrome: The BruFib Study. JACC Clin Electrophysiol. Published 27 August 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →